Kerendia

Chemical Namefinerenone
Dosage FormTablets (oral; 10 mg, 20 mg)
Drug ClassReceptor antagonists
SystemUrinary
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2021

Indication

  • Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kerendia (finerenone) Prescribing Information2021Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ